Queen’s University researcher receives New Investigator Award to advance groundbreaking extracellular vesicle research

Dr. Sheela Abraham has been named a Terry Fox New Investigator in support of her ground-breaking research on acute myeloid leukemia.

Dr. Abraham is one of seven talented, early-career scientists across Canada who will receive up to $450,000 over the next three years to support impactful cancer research through the 2024 Terry Fox New Investigator Awards program.

Her project focuses on how the microenvironments affects how acute myeloid leukemia develops, and what new and improved therapies will help us to target it.

“There’s a clear unmet need to improve survival outcomes in the acute myeloid leukemia space,” says Dr. Abraham, principal investigator and Assistant Professor in the Department of Biomedical and Molecular Sciences. “If we don’t understand the mechanisms behind this cancer, we’re never going to find a cure.”

Acute myeloid leukemia (AML) is the most common type of leukemia found in adults, however, the prognosis significantly differs depending on the patient’s age. With treatment, patients 65 and over have a 10 per cent or less chance of survival, whereas patients under age 45 have a 62 per cent chance of surviving at least five years after diagnosis.

To improve survival outcomes, Dr. Abraham will focus on the role of the microenvironment, particularly the role of extracellular vesicles (EVs) in cancer initiation, progression and remission.

More specifically, she will focus on EVs located in the bone marrow to understand if and how they support leukemic stem cells (LSC), which are responsible for the development and maintenance of leukemia.

“Extracellular vesicles are well-studied in the blood; however, there’s a missing link in that EVs found in the blood may not reflect what’s really going on in the bone, where leukemia begins and thrives. By understanding these overlooked bone marrow interactions, our results may highlight how LSCs establish a permissive environment, evade elimination and perpetuate disease,” she says.

Extracellular vesicles are tiny cell fragments released by all cells in the body. When released by cancer cells, it’s thought that their bioactive cargo may contain important information facilitating the exchange of messages between cells. But do EVs make AML worse? To find out, Dr. Abraham and her team will explore how LSCs communicate with other cells using extracellular vesicles.

She will also compare the composition of EVs in the bone marrow of patients diagnosed with AML with those of a healthy individual to see if they help or hinder the development of leukemia. Finally, she will investigate whether the behaviour of EVs can be targeted as a new and improved type of therapy.

Dr. Abraham hopes this groundwork will open the doors to future drug discoveries and contribute to earlier detection, ultimately improving survival outcomes for patients with this disease.

Learn more about Dr. Abraham’s lab and research.

SourceQueen’s University

Leave a Reply

Your email address will not be published. Required fields are marked *